Cancer-directed treatment using Tumor-Treating Fields spatially modulates the tumor microenvironment at the cellular and molecular levels, decreasing nanotube-based cellular networks of communication while creating a microenvironment more susceptible to immunotherapeutic strategies.

Novel human models of the lung and intestine are described and validated as preclinical in vitro tools for predictive profiling of T-cell-bispecific antibodies with expected on-target off-tumor risk.

Exploiting the metabolic consequences of Akt activation in prostate cancer for therapeutic interventions that circumvent Akt inhibition therapy.

Irradiation of normal human fibroblasts and mice in conditions mimicking standard external X-ray radiotherapy protocols highlights that noncancerous cells surrounding the planning target volume accumulate DNA single-strand breaks but almost no double-strand breaks, putting them in a pre-cancerous senescent state.

A novel first-in-class small molecule (ERX-11) that interacts with and disrupts the interactome of the estrogen receptor (ER), blocks the growth of ER-positive breast cancers, including those that are resistant to currently approved hormonal agents.

Genetic engineering of murine myeloid cells reveals the challenges in ectopic expression of chemiric receptors and provides a novel framework to endow them with tumor-specific cytotoxic ability.

An immunopeptidomic-based pipeline provides a tool for the identification of cancer therapeutic targets and generation of cancer oncolytic vaccines.

Inhibiting the RiBi pathway impedes both EMT and MET processes, enhancing chemotherapy efficacy and presenting a novel avenue to tackle advanced breast cancer treatment resistance.

Combined inhibition of oncogenic and epigenetic pathways results in a substantial decrease in the viability and growth of H3-K27M pediatric glioma models.

AIDPS derived by 76 machine-learning algorithm combinations in 13 independent multicenter cohorts exhibited superior capability than clinical traits and 86 published prognostic signatures and could serve as an ideal biomarker for stratified management and individualized treatment of pancreatic cancer.